532 related articles for article (PubMed ID: 35241494)
1. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
Li LL; Yu AY; Zhu M; Ma LY; Cao MH; Liu WL; Qin XB; Gao C; Han ZX; Wang HM
Arch Virol; 2024 May; 169(5):114. PubMed ID: 38700535
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
4. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.
Wei XL; Liu QW; Liu FR; Yuan SS; Li XF; Li JN; Yang AL; Ling YH
Oncoimmunology; 2021; 10(1):1938381. PubMed ID: 34235004
[TBL] [Abstract][Full Text] [Related]
5. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
Masetti M; Lindinger M; Lorenzen S
Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of Epstein-Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy.
Kim EJ; Chae H; Park YS; Ryu MH; Kim HD; Shin J; Park YS; Moon MS; Kang YK
Gastric Cancer; 2024 Jan; 27(1):146-154. PubMed ID: 38006567
[TBL] [Abstract][Full Text] [Related]
7. The clinical impact of testing for biomarkers in gastric cancer patients: a real-world cohort.
van der Sluis K; van Sandick JW; van Dieren JM; Vollebergh MA; Grootscholten C; van den Berg JG; Snaebjornsson P; Hartemink KJ; Veenhof AAFA; Chalabi M; Kodach LL
Histopathology; 2023 May; 82(6):826-836. PubMed ID: 36694277
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.
Pereira MA; Batista DAM; Ramos MFKP; Cardili L; Ribeiro RRE; Dias AR; Zilberstein B; Ribeiro U; Cecconello I; Alves VAF; Mello ES
J Surg Res; 2021 May; 261():130-138. PubMed ID: 33429221
[TBL] [Abstract][Full Text] [Related]
10. Immune Landscape of Epstein-Barr Virus-Associated Gastric Cancer: Analysis From a Western Academic Institution.
Yee EJ; Gilbert D; Kaplan J; van Dyk L; Kim SS; Berg L; Clambey E; Wani S; McCarter MD; Stewart CL
J Surg Res; 2024 Apr; 296():742-750. PubMed ID: 38368775
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
12. Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients.
Yin YX; Ling YH; Wei XL; He CY; Wang BZ; Hu CF; Lin WP; Nie RC; Chen JW; Lin JL; Zhou J; Xie JJ; Yun JP; Xie D; Xue LY; Cai MY
Front Immunol; 2022; 13():973085. PubMed ID: 36591236
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P
Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer.
Shoda K; Ichikawa D; Fujita Y; Masuda K; Hiramoto H; Hamada J; Arita T; Konishi H; Kosuga T; Komatsu S; Shiozaki A; Okamoto K; Imoto I; Otsuji E
Oncotarget; 2017 Apr; 8(17):28796-28804. PubMed ID: 28430637
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma.
Dong M; Wang HY; Zhao XX; Chen JN; Zhang YW; Huang Y; Xue L; Li HG; Du H; Wu XY; Shao CK
Hum Pathol; 2016 Jul; 53():25-34. PubMed ID: 26980034
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of Epstein-Barr virus DNA in plasma and stomach biopsies of patients with gastric cancer.
Sarshari B; Ravanshad M; Rabbani A; Zareh-Khoshchehreh R; Mokhtari F; Khanabadi B; Mohebbi SR; Asadzadeh Aghdaei H
Virus Genes; 2023 Jun; 59(3):351-358. PubMed ID: 36757510
[TBL] [Abstract][Full Text] [Related]
17. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
18. Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study.
Xie T; Liu Y; Zhang Z; Zhang X; Gong J; Qi C; Li J; Shen L; Peng Z
J Immunother; 2020 May; 43(4):139-144. PubMed ID: 32134806
[TBL] [Abstract][Full Text] [Related]
19. Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein-Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery.
Akimoto E; Kuwata T; Shitara K; Kawazoe A; Sakamoto N; Ishii G; Ochiai A; Kinoshita T
Ann Surg Oncol; 2023 Aug; 30(8):5227-5236. PubMed ID: 36934377
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers.
Sun Q; Fu Y; Chen X; Li L; Wu H; Liu Y; Xu H; Zhou G; Fan X; Xia H
Gut Liver; 2022 Nov; 16(6):875-891. PubMed ID: 35611665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]